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MACROMOLECULAR PRODRUG  
FOR THE TREATMENT OF ULCERATIVE COLITIS 
 
Ulcerative colitis is a chronic inflammatory bowel disease affecting the colon. 
More than 1 million Americans are affected[1], with the annual economic burden 
up to 14.9 billion[2] in the United States. By far, ulcerative colitis still lacks the cure 
and the current treatment strategies are limited due to severe side effects and in-
sufficient efficacy. The tofacitinib (Xeljanz) is the only approved oral medication by 
for adults with moderately-to-severely-active ulcerative colitis. But the related side 
effects and serious infections still have to be resolved. In the previous study in our 
lab, the researchers have successfully developed and characterized multiple hy-
drophilic prodrug formulations (P-Dex-D and P-Tofa). We suppose these prodrugs 
can be orally administered with reduced systemic exposure according to their in 
vivo release profiles. In this study, these prodrugs are administered orally to dex-
tran sulfate sodium induced ulcerative colitis murine model. The results demon-
strated that these drugs can effectively ameliorate colitis and reduced side effects 
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1.1 Ulcerative colitis  
 Ulcerative colitis is a chronic, idiopathic inflammatory disease characterized by 
disorder of colonic mucosa, starting in the rectum and extending to proximal co-
lon[3]. It is a common and costly disease, affecting approximately 1 million Ameri-
cans[1], with the annual economic burden up to 14.9 billion[4] in the United States. 
The accelerating incidence and prevalence of UC worldwide have made it a global 
disease[3, 5]. The disease most commonly presents with bloody stool(hemato-
chezia) and diarrhea, in addition to weight loss, abdominal pain, perianal disease, 
signs of malnutrition and so on[6]. Endoscopy is the only way to confirm the diag-
nosis of UC[3]. 
The peak age for UC occurrence is around 30 years[7].  Several studies have 
revealed that genetics, environment, dietary[8] and smoking factors are playing 
important roles in affecting the risk of UC even the etiology is unknown.  
UC is incurable and to be continued throughout life[7]. Currently, 5-aminosali-
cylic acid(5-ASA) is the first-line therapy for mild to moderate ulcerative colitis and 
corticosteroids can be added as the second-line treatment when the 5-ASA ther-
apy is ineffective. Moderate to severe disease is managed by immunosuppres-
sants and biological drugs(anti-TNF-α or anti-integrin therapy)[3, 8]. Up to 45% of 
UC patients need surgical intervention[9]. 
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1.2 Main challenges for oral drugs 
As we know, the oral route is the most attractive because of its convenience 
and patient compliance. However, for ulcerative colitis, oral drugs are of limited 
use and have encountered many challenges, due to the complex altered physio-
logical environment caused by inflammation.  
An oral drug must traverse the entire digestive tract and stay almost intact be-
fore reaching the distal part. Some literature reports that the transit time for in-
flammatory bowel disease patients in the small intestine is 30% higher than that 
in healthy groups (2-6h), while colonic transit time significantly varies from 6-70h, 
with faster average duration (24h) compared with that in healthy groups (around 
51h)[10].In addition to the adverse transit time, the drugs might be early metabo-
lized in the gastrointestinal tract by enzymatic or microbial degradation. Common 
enzymes include as β-glucuronidase, β-xylosidase, glycosidase, dextranase, es-
terase, cyclodextranase, α-arabinosidase, β-galactosidase, nitroreductase, 
azoreductase, deaminase, urea hydroxylase, etc.[11, 12] Normally, luminal PH 
rises from the acidic stomach to reach 6 in the duodenum and continues to in-
crease to 7.5 in the ileum. After experiencing a fall to 5.5 in the caecum, PH 
gradually rises to 6.7 in the rectum.  However, the luminal PH range in inflamed 
colon sites has a shift to lower PH, especially for severe colitis[13, 14]. 
To summarize, oral formulations are challenged by the complexity of various 
gastrointestinal barriers. The transit time, mucus charge, particularly pH and en-
zymes are playing important roles in colon delivery designs.  
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1.3 Potential target strategies 
Colon target systems can avoid systemic absorption, improve efficacy and bi-
oavailability. To target inflamed colon, the main reported strategies focus on the 
design of delayed or controlled release systems, such as charge-, size, time-, pH-, 
microflora-, enzyme- dependent systems[15]. However, considerations should be 
made during the development process for the varied physiological conditions and 
individual variability. Sometimes, conflicting results were reported for the same tar-
get mechanisms. 
1.4 Animal models 
In the field of ulcerative colitis, the dextran sulfate sodium (DSS) model is the 
most commonly used murine model. DSS is a polyanionic derivative of dextran. It 
works by chemical damage to intestinal epithelium to increase permeability, thus 
increasing the exposure of luminal antigens and enteric bacteria[16]. Normally, the 
inflammation is limited to colon while the small intestine is involved as a very small 
portion[17]. The colitis caused by DSS is like ulcerative colitis from the clinical per-
spective, characterized by diarrhea, bloody stool, decreased body weight, anemia, 
even death. The typical symptoms of colitis usually appear on day 3 and are max-
imally expressed by day 7[18]. Besides, this model is comparatively simple, cheap 
and reproducible. By adjusting the intake concentration and duration, the colitis 
could be acute or chronic, moderate or severe.  
In our study, we chose two cycles DSS induction process, each cycle contains 
7-day DSS intake followed by 7-day normal drinking water for washing out. In this 
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case, the first cycle could be considered as the acute phase while the second cycle 
as the chronic phase. The therapeutic efficiency could be observed in both phases, 
especially under the conditions that conflict treatment results of dexamethasone 
were reported.  
There are other murine models reported to mimic ulcerative colitis, such as 
acetic acid-induced colitis by similar chemical damage mechanism, and oxazo-






IN VIVO EVALUATION OF P-DEX-D THERAPEUTIC EFFICACY AND 
TOXICITY IN ULCERATIVE COLITIS MURINE MODEL 
2.1 Introduction 
 Glucocorticoids are potent drugs that are commonly prescribed for acute 
exacerbations as the second-line therapy to induce remission in ulcerative colitis. 
Their immunosuppressive and anti-inflammatory effects are realized by their cog-
nate receptor - glucocorticoid receptor[19]. But the longtime use is not recom-
mended due to its undesirable side effects, such as osteoporosis, hypertension, 
cataracts, glaucoma, high risk of infections. In the previous study in our lab, the N-
(2-Hydroxypropyl) methacrylamide (HPMA) and dexamethasone (Dex) copoly-
mers (named P-Dex-D) were synthesized by reversible addition−fragmentation 
chain transfer (RAFT) copolymerization as described previously (paper un-
published). On the one hand, the HPMA copolymers are widely used as a safe 
hydrophilic macromolecular carrier.  On the other hand, according to the slow re-
lease profile in vitro, we suppose the ester bond which can be cleaved by increased 
esterases and decreased PH environment in inflamed sites possibly improve the 
target delivery profile. The study in this chapter further investigated the potential 




2.2 Materials and instruments 
2.2.1 Materials 
N-(2-Hydroxypropyl) methacrylamide (HPMA), S,S′-bis(α,α′-dimethyl-α″-acetic 
acid)-trithiocarbonate (CTA), were prepared as described previously[20]. Dexa-
methasone base and dexamethasone sodium phosphate were separately pur-
chased from LETCO medical (Decatur, AL, USA) and Hawkins (Minneapolis, 
MN, USA).  Dextran sulfate sodium salt (DSS, Mw Ca 40,000) to induce colitis 
was provided by Alfa Aesar (Ward Hill, MA, USA). ColoScreen FOB test kit for di-
agnosing the presence of hematochezia was purchased from Helena Laborato-
ries (Beaumont, Texas, US). The surgical lubricant was purchased from HR 
Pharmaceuticals. Inc (Surgilube®, New York, PA, USA).  Dulbecco’s modified 
eagle medium (DMEM) for cell culture was purchased from Life Technologies 
Limited (UK). 
C57BL/6J female (8-week old) mice were purchased from Jackson Laborato-
ries. Prior to the start of the study, mice were allowed to acclimate for one week 
and given ad libitum access to food and water. All animal experiments were per-
formed according to a protocol approved by the Institutional Animal Care and 
Use Committee (IACUC) of the University of Nebraska Medical Center (UNMC). 
2.2.2 Instruments 
Blood glucose was monitored by one Touch Basic blood glucose monitoring 
system (Lifescan Europe, Switzerland), accompanied by test strips (Lifescan Eu-
rope, Switzerland). The sectioning of paraffin-embedded colon samples was 
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completed using a Leica RM2255 rotary microtome (Buffalo Grove, IL, USA). 
Histological slides after H&E staining was scanned by a VENTANA iScanner HT 
(Tucson, AZ, USA). The colonoscopy was completed by the endoscope, with the 
outside diameter of 1.85 mm and LED light all purchased from Gradient Lens 
Corporation® (Rochester, NY, USA), and is accompanied with a camera from 
Amscope (Irvine, CA, USA). Variable-Speed Peristaltic Tubing Pump was pur-
chased from Fisher Scientific (Hampton, NH, USA) for the air inflation and liquid 
perfusion. An X-ray micro-CT system (Skyscan 1172, S/N=10j01156, Hamama-
tsu C9300 11Mp camera) was used to assess bone quality.  
2.2.3 Synthesis and characterization of HPMA copolymer conjugate P-Dex-D 
The polymers were prepared as reported previously (Figure 1). The monomer 
D dissolved in anhydrous methanol was separately copolymerized with HPMA, 
with 2,2″-azobis (isobutyronitrile) (AIBN) as an initiator and S,S′-bis(α,α′-dimethyl-
α″-acetic acid) trithiocarbonate (Chain transfer agent, CTA) as the Reversible ad-
dition-fragmentation chain transfer (RAFT) agent under argon at 45 °C for 48 h. 
The product was then purified on an LH-20 column and dialyzed followed by ly-
ophilization. The weight average molecular weight (Mw) is around 31.9 ×103 g/mol, 
and the polydispersity index (PDI) is 1.48, both of which were determined by size 
exclusion chromatography (SEC) with an ÄKTA fast protein liquid chromatography 
(FPLC) system. Both the UV-Vis method and hydrolysis method followed by high-
performance liquid chromatography (HPLC) measurement were used to determine 
the Dex loading, which is 303.66 μmol/g (12%).  
8 
 
The in vitro release profile in different pH buffers (pH 5.0 acetate buffer, pH 6.0 
acetate buffer, pH 7.0, pH7.4 and pH 8.7 phosphate buffer, pH 11 sodium car-
bonate buffer, human serum and rat serum) demonstrates that the free Dex re-
lease in the acidic or neutral environment is very slow. In this case, we can 
suppose that the stability of the ester-linked polymers is able to target P-Dex-D to 

















2.2.4 DSS-induced colitis and drug treatment 
Twenty-eight 9-week female C57BL6/J mice were randomly assigned into five 
groups. Group 1(n=5) was designated as a healthy control group with normal water 
intake and no treatment. Group 2-5 were designed as saline(n=5), dexamethasone 
sodium phosphate(n=5, equivalent dex dose=1mg/kg/d), dexamethasone sodium 
phosphate(n=8, equivalent dex dose=5mg/kg/d), P-Dex-D(n=5, equivalent dex 
dose=5mg/kg/d) treated groups, received 2 cycles of 2% DSS for the chronic colitis 
induction. Each cycle includes seven-day continuous 2% DSS in drinking water 
followed by a seven-day continuous plain water washout. In each treatment group, 
the drug was administrated daily by oral gavage from day 7 post induction to the 
end of the study for 21 days.  
2.2.5 Evaluation of in vivo anti-inflammatory activity  
2.2.5.1 Disease activity index evaluation  
Body weight, stool consistency, and hemoccult positivity were examined and 
recorded daily for all the animals. The disease activity index (DAI) scores, an in-
dicator of the severity of colitis, were determined based on a standard scoring 
system as previously described in the literature (Table 2.1)[21, 22]. The DAI scor-
ing used a 0–3 scale for the change of body weight, and the severity of diarrhea 





Score Weight loss Stool consistency Hemoccult (Blood stool) 
0 none Normal Negative hemoccult 
1 1-5% (>0) mild soft Positive hemoccult 
2 6-10% (>5) Very soft; wet Blood traces in stool visible 
Table 2.1 The scoring criteria of the disease activity index based on weight loss, 




2.2.5.3 Colonoscopy and Colitis Scoring 
 Reported classic endoscopic findings in ulcerative colitis include erythema, 
vascular pattern loss, granularity, erosion, friability, bleeding, and ulceration[3]. 
To avoid the inaccurate measurement of DAI caused by contact damage from 
the colonoscopy, the colonoscopy experiment was done on day 28. After gentle 
air inflation into the colon, the endoscope equipped with light and camera was 
used for colonoscopy to image the colon surface. For C57/BL6 mice, the location 
for colonoscopy is approximately 1cm away from the anus. The images were 
scored by a gastroenterologist (DDE, who was blinded to the treatment groups) 








Fibrin visible Granularity of the 
mucosal surface 
0 Transparent  Normal None None 
1 Moderate Moderate Little Moderate 
2 Marked Marked Marked Marked  
3 Nontransparent Bleeding Extreme Extreme 




2.2.5.3 Histological assessment of colitis   
The mice were euthanized on the 29th day after an oral glucose tolerance 
test. Major organs (heart, liver, spleen, lung, kidney, adrenal gland, colon, femur 
and lumbar) were collected and fixed in formalin after sacrifice. The length and 
weight of colon were measured. The weight of adrenal gland was recorded after 
fixation in formalin for 24h. 
The longitudinally opened colons were rolled with mucosa outward into a 
swiss roll from distal to proximal part. After fixation, the colons were embedded in 
paraffin, sectioned (5μm thickness) and stained with hematoxylin and eosin 
(H&E). The stained slides were scanned using a high-throughput bright-field slide 
scanner and graded by a pathologist (SML, who was blinded to the group ar-
rangement) according to the degree of inflammation, the extent of inflammation, 
regeneration, crypt damage and percent involvement. The histological grading 
criteria were shown in Table 2.3. 




Parameters  Score  Histological features 
Inflammation 0  None 
 1 Slight 
 2 Moderate 
 3 Severe 
Extent 0 None 
 1 Mucosa 
 2 Mucosa and submucosa 
 3 Transmural 
Regeneration 0 Complete regeneration or nor-
mal tissue 
 1 Almost complete regeneration 
 2 Regeneration with crypt deple-
tion 
 3 Surface epithelium not intact 
 4 No tissue repair 
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Crypt damage 0 None 
 1 Basal 1/3 damage 
 2 Basal 2/3 damage 
 3 Only surface epithelium lost 
 4 Entire crypt and epithelium lost 
Percent involvement 1 1–25% 
 2 26–50% 
 3 51–75% 
 4 76–100% 




2.2.6 Side effects assessment of polymers   
2.2.6.1 Adrenal gland observation  
 It is well known that the chronic administration of high dose exogenous gluco-
corticoid might cause the adrenal insufficiency[24]. To test the degree of central 
suppression and adrenal atrophy, the weight of adrenal gland was recorded after 
fixation in formalin for 24h. The reason we did not record the fresh adrenal gland 
weight is that the original weight exceeded the precision limit of balance. 
2.2.6.2 Oral glucose tolerance test (OGTT)  
 The diabetogenic effect caused by glucocorticoid administration is often con-
sidered as insulin resistance. Briefly, the Dex treatment groups might lack the 
ability to regulate blood glucose after glucose intake, due to the insufficient insu-
lin release. To test this, mice were fasted overnight (for 16 hours) on day 28. In 
the next morning, they were administrated weight-dependent glucose(1g/kg) by 
gavage, and blood glucose on the leg of the mice was measured at 0, 30, and 
120 minutes. 
2.2.6.3 Micro-CT analysis of bone quality 
 The femur was collected and fixed in formalin for more than 2 days after eu-
thanasia. The left femur bone quality was analyzed by a Skyscan 1172 micro-CT 
system according to the following parameters: voltage,  55kv; current, 181μA; 
pixel size, 8.89μm; exposure time, 825ms; filter, 0.5mm aluminum; rotation step, 
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0.4 degree; frame average, 4; random movement, 10; 360 rotation, off. The re-
gion of interest is the distal femur [25] of 100 slices (0.89mm), 40 slices 
(0.36mm) from growth plate to metaphysis.  
2.2.6.4 Cytotoxicity study 
 For cytotoxicity studies, mouse macrophage cell line (J774, ATCC, VA) and 
human epithelial cell line (Caco-2, ATCC, VA) were cultured in Dulbecco's Modi-
fied Eagle Medium (L-glutamine, high glucose) supplemented with 100 U/mL pen-
icillin, 100 µg/mL streptomycin, and 10% heat-inactivated FBS. During the 
experiment, cells were incubated in a humidified 5% CO2 incubator at 37 ºC. Cells 
were seeded at 1104 cells/well in 96-well plates and incubated for 24 hours. With 
saline as the vehicle, different concentration groups of dexamethasone sodium 
phosphate (0.1µM, 1µM, 10µM) and P-Dex-D (1µM, 10µM, 100µM) were added to 
each well. The cell viability was determined by MTS cell proliferation colorimetric 
assay kit (BioVision, California, USA) at 490nm. 
2.2.7 Statistical method 
 Comparisons were made by one-way ANOVA followed by a post hoc Tukey’s 
test for multiple comparisons using GraphPad Prism Software. Data were ex-




2.3 Results  
2.3.1 Survival curve 
 No mice were found dead in healthy, saline and P-Dex-D groups while the 
mortality in both free Dex treatment groups is significantly high. It is obvious that 
a higher dose lead to more severe side effects. Even we set a lower dose free 









2.3.2 Disease activity evaluation 
The hallmark symptom of UC is bloody diarrhea, sometimes accompanied by 
losing weight. In Fig.2.4, the diarrhea was observed instantly on day 1. The body 
weight loss and hemoccult were observed from day 5. After one week of treat-
ment, both Dex and P-Dex-D treatment groups showed a trend to ameliorate the 
stool consistency. But for the sum of the DAI score, no obvious remission effect 
in the acute phase was found in Dex or P-Dex-D treatment groups compared 
with the saline group.  
In the chronic phase, the second 14-day cycle, the deteriorating conditions in 
both Dex groups even lead to the death of mice. Higher Dex dose, earlier and 
higher mortality.  We suppose it was caused by the severe systemic absorption 
effect. Compared with the saline group, the DAI in the P-Dex-D group obviously 
has a decreased trend and the statistical difference (P ≤ 0.05) was observed on 
day 20. From day 23 to day 28 except day 24, no significant difference was ob-
served between P-Dex-D and healthy groups, while a significant difference (P ≤ 
0.05) always existed between saline and healthy groups. 
Since the inflammation would shorten colon length and thicken bowel wall, 
the colon length and weight were measured for further observation. In Fig2.6 A, 
no difference was found between groups except that the Dex group showed 
shorter colon length. But the colon weight/length ratio was significantly reduced 




Figure 2.4 Body weight, stool consistency and hemoccult positivity score change 




Figure 2.5 Disease activity index (DAI) in mice. (A) The change of DAI scores 
summarized by the sum of three separate scores after DSS induction. (B) DAI 




 D8 D9 D10 D11 D12 D13 D14 
Healthy vs. 
Saline **** **** **** **** ** * *** 
Healthy vs. 
P-Dex-D **** ** **** **** ** * ** 
Healthy vs. 
1mg/kg Dex **** **** **** **** ** ** *** 
Saline vs. 
P-Dex-D ns ns ns ns ns ns ns 
Saline vs. 
1mg/kg Dex ns ns ns ns ns ns ns 
P-Dex-D vs. 
1mg/kg Dex ns ns ns ns ns ns ns 
 
 D15 D16 D17 D18 D19 D20 D21 
Healthy vs. 
Saline *** *** **** ** *** **** **** 
Healthy vs. 
P-Dex-D *** *** ** ** ** ** *** 
Healthy vs. 
1mg/kg Dex **** **** **** **** **** **** **** 
Saline vs. 
P-Dex-D ns ns ns ns ns * ns 
Saline vs. 
1mg/kg Dex ns ns * * * ** ns 
P-Dex-D vs. 
1mg/kg Dex * ns ** * ** **** ** 
 
 
 D22 D23 D24 D25 D26 D27 D28 
Healthy vs. 
Saline ** ** * * * * * 
Healthy vs. 
P-Dex-D * ns * ns ns ns ns 
Healthy vs. 
1mg/kg Dex **** **** **** ** *** ** ** 
Saline vs. 
P-Dex-D ns ns ns ns ns ns ns 
Saline vs. 
1mg/kg Dex **** * *** ns * * * 
P-Dex-D vs. 





Table 2.4 The statistical analyses of the DAI score of the mice from different treat-
ment groups from Day9 to Day 28. One-way analysis of variance (ANOVA), fol-
lowed by Tukey’s post hoc test to account for multiple comparisons, was used for 
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data analysis using GraphPad Prism Software. The statistically significant differ-
ence (P ≤ 0.05) between saline and P-Dex-D treatment groups was only found on 




Figure 2.6 Quantitative analysis of colon after sacrifice. (A) Colon length at eu-





2.3.3 Colonoscopy evaluation  
 The representative recorded images (Fig2.7A) were chosen by a gastroenter-
ologist (DDE). In the healthy control group, the vascular was distinct without any 
abnormal signs in the colon. For P-Dex-D treated group, the overall colon condi-
tions on day 28 were similar to that in the healthy group. In contrast, the loss of 
vascular, surface irregularities, even bleeding phenomenon were observed in 
most mice in saline and Dex-treated groups after three-week treatment. The co-
lonoscopy images demonstrated the significant remission of inflammation in the 
P-Dex-D group. The colonoscopy scoring results (Fig2.7B) also showed a de-
creasing trend of severity in the P-Dex-D treated group, and no statistically signif-





Figure 2.7 Colonoscopy analysis on day 28. (A) Colonoscopy images recorded in 
the distal colon. Blue arrow indicates loss of vascular pattern; red arrow indicates 
bleeding; and white arrow indicates irregularities. (B) Colonoscopy score results 
evaluated by a gastroenterologist (DDE) according to the endoscopic colitis grad-
ing criteria in Table 2.2. *, P ≤ 0.05. 
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2.3.4 Histological evaluation  
 Histology evaluation is the most robust method to observe therapeutic effi-
cacy since the entire colon can be overviewed comprehensively. Intact epithe-
lium, inflammatory cell infiltrates in mucosa and submucosa, severe crypt 
damage were observed in saline and Dex-treated groups. Slight inflammation 
and negligible crypt depletion were found in the P-Dex-D group. The overall com-
parison demonstrated the good therapeutic efficacy of the prodrug P-Dex-D. Ad-
ditionally, the histological observation correlated well with the disease activity 
index results and colonoscopy evaluation. The statistically significant difference 
was found between the P-Dex-D group and saline or free Dex groups, while no 





Figure 2.8 Histology analysis. (A) Representative images after H&E staining at 
four times magnification. Blue arrow indicates intact epithelium; red arrow indi-
cates inflammatory cell infiltration; and black arrow indicates crypt damage. (B) 
Histological score results evaluated by a pathologist (SML) according to the his-




2.3.5 Adrenal gland evaluation 
The degree of adrenal atrophy caused by overdose of glucocorticoids can be 
well demonstrated by the change of adrenal weight. The adrenal gland weight at 
necropsy was too light to be detected by 0.1mg analytical balance. So, we rec-
orded adrenal weight after fixation in formalin. The results indicated a trend of ad-
renal atrophy after the daily administration of free Dex while there is no reduced 





Figure 2.9 Adrenal gland weight evaluation. No statistically significant difference 




2.3.6 Oral glucose tolerance test 
 The exclusive hormone, insulin, can lower plasma glucose concentration to 
maintain glucose homeostasis in vivo. However, the long-term use of a high dose 
of glucocorticoid often results in insulin resistance, leading to the disability to ad-
just blood glucose[26]. The insulin compensation was clearly observed in mice 
treated with free Dex while other groups showed similar normal adaptative blood 
glucose profiles. This implies a certain elevated function of islet cells to compen-
sate for the increased Dex-induced peripheral insulin demand[27]. We postulate 











2.3.7 Micro-CT analysis for bone quality 
 The distribution of GC receptors in osteoblasts, growth plate chondrocytes 
and other locations in bone marrow leads to osteoporosis by systemic absorp-
tion[28]. We analyzed the distal femur (left leg) by Micro-CT and measured bone 
architecture parameters: the bone mineral density (BMD), the ratio of bone vol-
ume to tissue volume (BV/TV), and trabecular thickness(Th)[29]. No considerable 
difference between these groups was observed in bone mineral density and the 
ratio of bone volume to tissue volume. The significantly reduced Th value in sa-
line group compared to healthy mice could be contributed to the osteoporosis 
caused by ulcerative colitis. Statistical difference was found between saline and 
P-Dex-D groups regarding Th, demonstrating the good therapeutic effect and de-





Figure 2.11 Parameters of trabecular bone structure. (A) Bone mineral density. (B) 
The ratio of bone volume to tissue volume. (C) Trabecular thickness. *, P ≤ 0.05; 




Figure 2.12 Trabecular bone structure. (A) An overview of the region of interest 
(red region) in the distal femur. (B) The bone structure in ROI (representative im-




 To evaluate the cytotoxicity in vitro, macrophage and human intestinal epithe-
lial cell lines were used. The drug concentration was determined mainly by the 
oral gavage dose. DMEM without FBS was used as vehicle and control groups. 
Considering the drug content and slow release of Dex from P-Dex-D in vitro, we 
selected 100µM P-Dex-D to correspond to 10µM Dex dosage. In this study, we 




Figure 2.13 Cytotoxicity evaluation. (A) Cell viability in mouse macrophage-like 
cells(J774). (B) Cell viability in the intestinal epithelial cell line (Caco-2). No sta-





2.4 Discussion  
 Ulcerative colitis is a multifactorial chronic inflammatory disease that mainly 
affects large intestine which can’t be cured. It is characterized by mucosal inflam-
mation, starting from rectum and extending to the proximal colon. The hallmark 
phenomenon is bloody diarrhea. As anti-inflammatory agents, glucocorticoids are 
often used to treat mild to moderate ulcerative colitis clinically by topical or sys-
temic administration as the second-line therapy. Although it effectively induces 
remission, Dex is not effective in maintaining remission. Besides, as a low molec-
ular weight drug, high dosage and long-term use of Dex often result in serious 
adverse effects due to limited targeting of inflamed sites.  
For oral therapy, the multiple physiological barriers, various enzyme degrada-
tion, complex PH environment, shorter colon transit, all raise challenges for oral 
formulation development. Currently published strategies mainly focused on PH-, 
size-, charge-, time-, enzyme- dependent delivery systems and some signifi-
cantly increased clinical remission. Literature has also reported some advanced 
research of oral steroids to minimize systemic activity by utilizing first-pass liver 
metabolism or prolonged release profile. Our previous study successfully devel-
oped the HPMA-conjugated prodrug with cleavable ester bond. The HPMA-
based conjugate with comparatively high drug loading (13% Dex content) signifi-
cantly improved the solubility. The surface PH of colonic mucosa ranging from 
7.1 to 7.5[30] is consistently considered high in vivo. The intraluminal PH in the 
colon is also comparatively higher than other parts in the gastrointestinal tract, 
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except for extremely low PH (2-4) observed in severe active colitis. The slow re-
lease profile(approximately 1% per day) in acidic PH environment enables the 
delivery of the most intact drug to the distal gastrointestinal tract and further con-
trolled release by upregulated esterase in inflammatory sites[31]. Additionally, 
Passive accumulation could be achieved by the leaky endothelium, which con-
tributes to higher permeability of conjugates compared to healthy tissues. So, we 
suppose that the design of prodrug P-Dex-D potentially targets to the inflamed 
colon, reduces systemic exposure, achieves controlled release by enzyme-re-
sponsive degradation. 
In the present study, we evaluated the therapeutic effect and potential side ef-
fects in a DSS-induced murine model. Compared to the high mortality in free 
Dex-treated groups, all mice survived in the P-Dex-D treatment group. This im-
plies the reduced systemic exposure and potential target to inflamed colon sites. 
The daily observation of the DAI score showed a trend of P-Dex-D treatment to 
ameliorate inflammation compared to other treatment groups in the aspects of 
body weight and bloody diarrhea, especially in the second cycle. Although no 
statistically significant difference in colonoscopy score was found between saline 
and P-Dex-D groups, there is no statistically significant difference observed be-
tween healthy and P-Dex-D groups. The wide PH range and conflicting observa-
tion of PH change in the colon might imply the inter-individual variability in the 
endoscopy due to different Dex release profiles[32]. The statistically significant 
difference between P-Dex-D and saline groups in colon density, histology score 
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after sacrifice further demonstrated P-Dex-D effectively induces remission. How-
ever, the complete resolution was not achieved with P-Dex-D treatment even 
there is no statistical difference between P-Dex-D treated group and healthy con-
trols from the aspects of DAI score on day 28, histological and colonoscopy eval-
uation. Obviously, additional dose escalation experiment and different chronic 
strategies are necessary to further advance P-Dex-D treatment.  
 In addition, to assess the underlying side effects, we compared the adrenal 
weight change, oral glucose tolerance, bone loss in the distal femur and cytotoxi-
city. Expectedly, there is a trend for free Dex group to cause adrenal gland atro-
phy and overexpressed glucose tolerance, while the observation of P-Dex-D 
treated mice corresponded to those levels in healthy and saline-treated mice. 
One of the severe side effects caused by GC is osteoporosis. No bone loss was 
found in the P-Dex-D treated group. Regarding the cell cytotoxicity in macro-
phage or human epithelial cells, no cytotoxicity was found after P-Dex-D treat-
ment. In a word, a comparative safety profile was proved by the above 
experiments.  
DSS model is chemical-induced colitis characterized by leaky epithelium in 
the colon. It has been widely perceived as a good colitis model mostly owing to 
the similarities to human colitis in aspects of pathology. From this murine model, 
both the acute phase and chronic phase could be utilized to evaluate therapeutic 
efficacy.  The little therapeutic efficacy in Dex and P-Dex-D groups in the first cy-
cle observed from DAI score corresponds to some reports that Dex was not 
working in the acute phase.  Further improvement of drug administration duration 
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on the chronic model is needed. To comprehensively investigate the therapeutic 
efficacy and side effects, other murine models by different induction mechanism 
could be used to evaluate P-Dex-D treatment, such as the T-bet-/- RAG2-/- Ul-
cerative Colitis (TRUC) model, which spontaneously develops juvenile ulcerative 
colitis by damaging transcriptional regulatory T-bet in RAG2-/- mice[33].  
To better understand of drug release in vivo, the release profiles in acidic 
stomach PH, in the presence or absence of esterase respectively would be fur-
ther investigated. In addition, the on-going optical imaging-based P-Dex-D biodis-
tribution and immunohistochemistry analysis are expected to profile more details 
in vivo.   
Even non-toxic and biocompatible HPMA benefits hydrophobic drug delivery, 
considerations should be taken due to its non-biodegradable property. In the pre-
sent study, the molecular weight was designed at 35kDa, which is below the mo-
lecular weight threshold of 45kDa for HPMA copolymer in the aspect of 
elimination. But the slow excretion rate via the hepatobiliary route still raises a 
safety concern, especially for prolonged use in chronic disease. To address the 
underlying weakness, a degradable HPMA copolymer is supposed to be further 
developed.  
2.5 Conclusion  
 In this study, the therapeutic efficacy of the HPMA copolymer P-Dex-D was 
successfully validated in the treatment of the DSS-induced chronic ulcerative co-
litis murine model. We postulate the potential target delivery mechanism is the 
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passive targeting to the leaky epithelium and controlled release of Dex by ester-
ase responsive ester bond in the copolymer. The safety profile further addressed 
the excess systemic exposure of free Dex. The superior therapeutic efficacy and 










IN VIVO EVALUATION OF P-TOFA THERAPEUTIC EFFICACY AND 
TOXICITY IN ULCERATIVE COLITIS MURINE MODEL 
  
3.1 Introduction  
As mentioned in chapter 2, ulcerative colitis still lacks the cure, especially in 
the aspect of oral formulations. As the first developed Janus Kinase inhibitor, to-
facitinib (Tofa) was used to treat moderately to severely active rheumatoid arthri-
tis as add-on therapy of methotrexate. It effectively inhibits JAK3,  with a lower 
extent to inhibit JAK1 and JAK2, to block the Janus Kinase pathway involved in 
proinflammatory cytokine signaling[34]. In 2018, it (Xeljanz) was approved by the 
Food and Drug Administration (FDA) as the first oral medication for adults with 
moderately and severely active ulcerative colitis[35]. But the related serious in-
fections and side effects, such as neutropenia and thrombocytopenia caused by 
JAK2 involvement, still must be resolved.  
In our previous study, a macromolecular Tofa prodrug (P-Tofa) was synthe-
sized and the significant inflammation amelioration by intravenous administration 
was validated in a murine colitis model. To further investigate the potential in oral 




3.2 Materials and Instruments 
3.2.1 Materials 
N-(2-Hydroxypropyl) methacrylamide (HPMA), S,S′-bis(α,α′-dimethyl-α″-acetic 
acid)-trithiocarbonate (CTA), were prepared as described previously. (synthesis 
and evaluation of a well-defined HPMA copolymer) Tofacitinib citrate and Tofa-
citinib base were both purchased from Jinlan Pharm-Drugs Technology Co, Ltd. 
(Hangzhou, China). IRDye® 800CW carboxylate was provided by LI-COR, Inc. 
(Lincoln, NE, USA). DSS and related materials such as hemoccult test kit were 
prepared as described in 2.2.1.  
C57BL/6J female (8-week old) mice were purchased from Jackson Laborato-
ries and used for the therapeutic efficacy study. Swiss Webster male (8-week 
old) mice were purchased from Charles River Laboratories and used for biodistri-
bution study. Both mice were fed a standard diet ad libitum and maintained under 
standard housing conditions in the University of Nebraska Medical Center 
(UNMC) animal facility. All animal experiments were performed according to a 
protocol approved by the Institutional Animal Care and Use Committee (IACUC) 
of the UNMC. 
3.2.2 Instruments  
The biodistribution part was imaged by LI-COR Pearl® Impulse small animal 
imaging system (Lincoln, NE, USA). Other instruments were the same as men-
tioned in 2.2.2. 
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3.2.3 Synthesis and characterization of P-Tofa  
As reported previously[1, 36], HPMA and Tofa-containing monomer (molar ra-
tio=14:1) were dissolved in anhydrous dimethyl sulfoxide (DMSO) with AIBN as 
initiator and S,S′-bis(α, α′-dimethyl-α″-acetic acid)-trithiocarbonate (CTA) as the 
RAFT agent. The reaction was under the protection of argon and polymerized at 
60 °C for 40 hr. The resulting polymer was first purified by precipitation in ace-
tone/diethyl ether (v/v = 1:1, 200 mL) twice to remove the unreacted low molecu-
lar weight compounds, followed by dialysis with 25 kDa weight cutoff dialysis 
tubing in distilled water and final lyophilization. The weight average molecular 
weight (Mw) is around 30.4 ×103 g/mol, and polydispersity index (PDI) is 1.32, 
both of which were determined by size exclusion chromatography (SEC) with an 
ÄKTA fast protein liquid chromatography (FPLC) system. 
To quantify Tofa loading, P-Tofa was hydrolyzed in 0.01 N NaOH in CH3OH 
overnight, followed by neutralization and analysis triplicate with HPLC system 
(mobile phase: acetonitrile/water = 3/1; detection, UV 284 nm; flow rate = 1 
mL/min; injection volume = 20 μL). Finally, the Tofa loading in P-Tofa was found 
to be 14.07 wt%. The release rates of Tofa from P-Tofa prodrug at pH = 5.5 and 
7.4 were averaged at ~1.5%, 2% per day, respectively (Fig 3.2). 
P-Tofa labeled with IRDye® 800CW was achieved by dissolving IRDye® 
800CW carboxylate, N-(3-dimethylaminopropyl)-N’-ethylcarbodiimide hydrochlo-
ride (EDC) and hydroxybenzotriazole (HOBtl) in DMF in dark at 21 C, followed 
by stirring for 30 min.  DIPEA and P-Tofa-APMA (from the RAFT polymerization 
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of HPMA, Tofa-containing monomer, APMA, AIBN, CTA in DMSO at 60 °C for 40 
hr) in DMF were added into the reaction mixture and then stirred overnight. The 
reaction solution was dialyzed to remove DMF and low molecular weight reac-
tants. P-Tofa-IRDye was then obtained via lyophilization. The final IRDye 800CW 
content is 8 × 10–6 mol/g of the conjugate. 
The data in this synthesis and characterization section were all from the previ-






Figure 3.1 A macromolecular prodrug of Tofacitinib (P-Tofa) [36].  (A) The synthe-









3.2.4 DSS-induced colitis and drug treatment 
Twenty 9-week female C57BL6/J mice were randomly assigned into four 
groups. Group 1(n=5) was designated as a healthy control group with normal water 
intake and no treatment. Group 2-4 were designed as saline (n=5), Tofa (n=5, 
10mg/kg/d), P-Tofa (n=5, equivalent Tofa dose=10mg/kg/d) treated groups, re-
ceived 2 cycles of 2% DSS for the chronic colitis induction. Each cycle includes 
seven-day continuous 2% DSS in drinking water followed by a seven-day contin-
uous plain water washout. In each treatment group, the drug was administrated 
daily by oral gavage from day 8 post induction to the end of the study for 21 days.  
3.2.5 Evaluation of in vivo therapeutic activity 
The entire process and scoring criteria of disease activity index evaluation, 
colonoscopy evaluation, histological assessment were the same as that de-
scribed in chapter 2.2.5.  
3.2.6 Biodistribution analysis of P-Tofa by optical imaging  
9-week male Swiss Webster mice (three mice per group per time point) were 
used for the optical imaging study. They were randomly divided into two groups: 
the healthy control group with normal water intake and the DSS group with 5% 
DSS in drinking water for five days. On day 6, all mice were all orally (by 22G ga-
vage needle) administrated weight-dependent dosage of P-Tofa-IRDye 
(40mg/kg) at the same time. They were euthanized 2h, 4h, 24h separately post-
treatment and the major organs (heart, liver, spleen, lung, kidney, adrenal gland, 
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mesenchymal lymph nodes, small intestine, and colon) were collected and imag-
ined by Pearl® Impulse small animal imaging system to evaluate the biodistribu-
tion of the IRDye-labeled P-Tofa. For better observation, the stools in the colon 
and small intestine were removed followed by a through washing process with 
saline.  
3.2.7 Statistical methods  
Comparisons for DAI score and biodistribution analysis were made by two-
way ANOVA test using GraphPad Prism Software. Other comparisons were 
made by one-way ANOVA followed by a post hoc Tukey’s test for multiple com-
parisons using GraphPad Prism Software. Data were expressed as means ± 
standard deviation. P-values ≤0.05 were considered as statistically significant. 
3.3 Results  
3.3.1 Disease activity index evaluation  
During the entire treatment process, no mice were found dead. In the first cycle, 
little therapeutic efficacy in Tofa or P-Tofa treated groups was observed when com-
pared with the saline control group. During the period of DSS exposure (day 15 to 
day 21) in the following chronic phase, the free Tofa treated group showed a trend 
of reduced DAI score while the undulant change of the sum of the score was ob-
served in P-Tofa group. In the last seven-day washout period, the steadily and 
faster decline in the P-Tofa treatment group was found compared to other groups. 
The Tofa treated group also has a lower score continuously in the last four days 
than that in the saline group, but still higher than that in the P-Tofa group. On day 
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25 post induction, saline and P-Tofa treatment group has statistical difference (**, 
P ≤ 0.01). The obvious amelioration of DAI by P-Tofa monitored in the last cycle 
indicated its potential therapeutic efficacy.  
To quantify the symptom of shorten colon length and thicken bowel wall, we 
measured the colon length and weight at necropsy. Although there is no statistical 
difference found in colon length, the ratio of colon weight to length did illustrate 
some differences. Compared to saline control, both Tofa and P-Tofa showed sig-
nificant improvement in colon conditions. The statistical difference (*, P ≤ 0.05) 
observed between Tofa and P-Tofa group indicated better efficacy of P-Tofa of the 
equivalent Tofa dosage. However, the statistical difference (*, P ≤ 0.05) between 
healthy and P-Tofa group demonstrated the complete resolution of chronic colitis 





Figure 3.3 Disease activity index (DAI) in mice. (A) The change of DAI scores 
summarized by the sum of three separate scores after DSS induction. (B) DAI 





 D22 D23 D24 D25 D26 D27 D28 
Healthy vs. 
Saline **** **** ** **** ** ** * 
Healthy vs. 
Free Tofa **** **** ** * * ns * 
Healthy vs. 
P-Tofa *** * ns ns ns ns ns 
Saline vs. 
Free Tofa ns ns ns ns ns ns ns 
Saline vs. 
P-Tofa ns ns ns ** ns ns ns 
Free Tofa 
vs. P-Tofa ns ns ns ns ns ns ns 
 
Table 3.1 The statistical analyses of the DAI score of the mice from different treat-
ment groups from Day22 to Day 28. Two-way analysis of variance (ANOVA) was 
used for data analysis using GraphPad Prism Software.  (*, P ≤ 0.05; **, P ≤ 0.01; 
***, P ≤ 0.001; ****, P ≤ 0.0001). On day 25 post induction, saline and P-Tofa treat-





Figure 3.4 Quantitative analysis of colon at euthanasia. (A) Colon length at eu-
thanasia; (B) colon weight-to-length ratio at euthanasia. (*, P ≤ 0.05; ***, P ≤ 




3.3.2 Colonoscopy evaluation 
The representative recorded images (Fig3.5A) were chosen by a gastroenter-
ologist (DDE). In the healthy control group, the vascular was distinct without any 
abnormal signs in the colon. The bleeding phenomenon was observed in most 
mice treated by saline, no more than half of mice treated by Tofa. However, the 
loss of vascular pattern and visible granularity were more common in Tofa and P-
Tofa groups, leading to higher colonoscopy score compared to saline treatment 
group. The unexpected statistical difference existed between saline and both 
Tofa and P-Tofa groups, which is totally in contrast to the observation from daily 
DAI and colon analysis. The conflicting endoscopic results might partly attribute 
to the insufficient record of distal colon conditions. No recorded video was a point 




Figure 3.5 Colonoscopy analysis on day 28. (A) Representative colonoscopy im-
ages recorded in the distal colon. (B) Colonoscopy score results evaluated by a 
gastroenterologist (DDE) according to the endoscopic colitis grading criteria in 
Table 2.2. (*, P ≤ 0.05; **, P ≤ 0.01; ****, P ≤0.0001)  
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3.3.3 Histological evaluation  
The histology evaluation was achieved from the H&E staining of colon tissue. 
The most severity of mucosal erosion and inflammation involvement were ob-
served in the saline group. Mild crypt damage and cell infiltration were observed 
in Tofa and P-Tofa groups. Comparatively, the overall severity of colonic inflam-
mation in both Tofa and P-Tofa groups were reduced, which corresponded to the 
trend in histological score accessed by a pathologist (SML). However, no statisti-
cal difference was found between each group. The statistical analysis illustrated 




Figure 3.6 Histology analysis. (A) Representative images after H&E staining at 
four times magnification. (B) Histological score results evaluated by a pathologist 




3.3.4 Biodistribution study 
 The near-infrared optical imaging-based analysis was used to analyze the P-
Tofa biodistribution in vivo and prove the potency of target delivery. At each time 
point post P-Tofa-IRDye administration, no drug retention was observed in major 
organs, including heart, liver, spleen, lung, kidney, adrenal gland and mesenchy-
mal lymph nodes. Despite some signals monitored in feces, stomach, and ce-
cum, prodrug was found to accumulate mainly in the colon. There is some signal 
observed in the small intestine. The stronger intensity in the small intestine in the 
sick group than healthy mice could be attributed to the partial damage to the epi-
thelium in small intestine caused by DSS exposure.  The statistical difference ob-
served between healthy and DSS induced groups in both inflamed colon and the 
small intestine demonstrated its specific target to inflammatory tissue. From the 





Figure 3.7 Near-infrared optical imaging-based analysis of P-Tofa biodistribution 
in the colon. (A) Representative images at 2h, 4h, 24h post P-Tofa-IRDye admin-
istration. (B) Quantitative analysis of intensity remaining in the colon. Two-way 






Figure 3.8 Near-infrared optical imaging-based analysis of P-Tofa biodistribution 
in the small intestine. (A) Representative images at 2h, 4h, 24h post P-Tofa-
IRDye administration. (B) Quantitative analysis of intensity remaining in the small 
intestine. (C) Comparison of quantitative intensity in the colon and intestine. Two-




3.4 Discussion  
As the first approved oral medication of UC, Tofa effectively induces and 
maintains remission[1]. However, the dose-dependent toxicities caused by simul-
taneous targeting of other JAK family members raise the concern in clinical use. 
Clinical studies reported that 3.8% of patients discontinued Tofa treatment in the 
first three months due to side effects, represented by pneumonia and shin-
gles[35]. We supposed P-Tofa might achieve target drug delivery by the cleava-
ble carbamate linker. In the present study, a DSS-induced chronic colitis model 
was used.  
From daily DAI observation in the second cycle, there was a trend that both 
Tofa and P-Tofa groups effectively ameliorated colitis. As indicated in the DAI 
score on day 28 and colon density, P-Tofa showed better therapeutic efficacy 
than an equivalent dosage of free Tofa. A similar trend was found in histological 
results. However, these results contrasted to endoscopic evaluation. Even bloody 
phenomenon was more common in the saline-treated group, the granularity and 
thicken colon were more often observed in P-Tofa, especially Tofa treated mice.  
According to an explanation given by the gastroenterologist, only photos without 
video was the main drawback for an overall evaluation. In this case, the histologi-
cal evaluation became more robust.  
In the biodistribution study[1], we sacrificed the mice at 2h, 4h and 24h post 
P-Tofa-IRDye gavage. No signal was found in organs and mesenchymal lymph 
nodes. As expected, after 2h, prodrug became accumulate in inflamed sites. 
Since the DSS induced colitis slightly damaged small intestine, the significantly 
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stronger signal was observed in both small intestine and colon in DSS-induced 
mice compared to healthy control. After one-day administration, the prodrug was 
no more observed in vivo.  The result revealed the potential inflammation target-
ing effect of P-Tofa.  
As mention in chapter 2, further evaluation should be done in other murine 
models. Besides, considering the excretion of prodrug wrapped in the feces, a 
dose escalation study is necessary.  
From the previous study, no cytotoxicity of P-Tofa was found in macrophage 
(J774) and human epithelial cells (Caco-2). But this study still lacks side effects 
evaluation, such as white blood cell count. More comprehensive toxicities are ex-
pected to be completed under the premise of further improved efficacy. 
3.5 Conclusion  
 To conclude, a macromolecular prodrug of JAK inhibitor (P-Tofa) was evalu-
ated in a DSS-induced colitis model. It showed superior therapeutic efficacy com-
pared to dose equivalent Tofa treatment. Due to the conflict endoscopic results, 
more efficacy and safety evaluation is necessary to further explore its potential 










 Based on HPMA macromolecular conjugates (P-Dex and P-Tofa) developed in 
the previous study, this study focused on the validation of therapeutic efficacy and 
evaluation of the safety profile. Both prodrugs showed significantly improved effi-
cacy compared with their parent drugs.  
4.2 Future plan 
 In the future, the optimization of polymeric carrier systems may also be ex-
plored for the further improved treatment of ulcerative colitis.  The further invest-
ment of the dosage and murine models would be done to fully establish their 
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